Effects of quinidine and verapamil on human cardiovascular α- adrenoceptors
Circulation, ISSN: 0009-7322, Vol: 97, Issue: 13, Page: 1227-1230
1998
- 24Citations
- 14Captures
- 1Mentions
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations24
- Citation Indexes24
- 24
- CrossRef16
- Captures14
- Readers14
- 14
- Mentions1
- References1
- Wikipedia1
Article Description
Background: The antiarrhythmic drugs quinidine and verapamil are known to block α1-adrenoceptors (αARs). αARs are a heterogeneous family of three subtypes (αA, αB, and αD), and little is known about the effects of quinidine and verapamil on the different human αAR subtypes. Methods and Results: Reverse transcriptasepolymerase chain reaction showed that all αAR subtypes are expressed in both human heart (atrium and ventricle) and the mesenteric artery. Pharmacological profiles of quinidine and verapamil actions on the αAR subtypes were characterized with Chinese hamster ovary cells stably expressing cloned human αAR subtypes. Radioligand binding studies showed that quinidine and verapamil had high affinities for all αAR subtypes. Also, both drags synergistically inhibited αAR-mediated inositol 1,4,5-triphosphate production at the clinical effective concentration range (1 μmol/L quinidine and 0.1 μmol/L verapamil). Conclusions: The results show that all αAR subtypes are expressed in the human cardiovascular system and that quinidine and verapamil may have a potent, synergistic inhibitory effect on the αARs. Clinically observed hypotension after quinidine plus verapamil can be explained by their synergistic inhibitory effects on human αARs.
Bibliographic Details
Ovid Technologies (Wolters Kluwer Health)
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know